More

• Teva Pharma buying MicroDose Therapeutx for $40M Monday, 17 Jun 2013 | 1:25 PM ET

  NEW YORK-- Teva Pharmaceutical Industries Ltd. said Monday that it is buying MicroDose Therapeutx for $40 million to build its pipeline of respiratory products. Teva, based in Israel, is one of the world's largest makers of generic drugs. U.S.-traded shares of Teva added 20 cents to $39.28 in Monday afternoon trading.

• U.S. judge approves FDA plan to drop limits on morning after pill Wednesday, 12 Jun 2013 | 9:38 PM ET

  Judge Edward Korman of the U.S. District Court in Brooklyn, New York, said the FDA proposal was "sufficient" to comply with his order to make emergency contraception widely available.

• Momenta Pharma rises following upgrade from UBS Thursday, 6 Jun 2013 | 4:43 PM ET

  NEW YORK-- Shares of Momenta Pharmaceuticals Inc. jumped Thursday after a UBS analyst upgraded the shares, saying she thinks it's more likely the company will be able to start selling a generic version of the multiple sclerosis drug Copaxone in the next few years.

• Sector Snap: Makers of morning-after pill rise Thursday, 6 Jun 2013 | 1:47 PM ET

  Shares of Teva Pharmaceutical Industries, which makes Plan B One-Step, increased 41 cents to $38.44 by midday. Shares of Perrigo Co., which has a two-pill pack, jumped nearly 3 percent to $116.47. And Actavis Inc. shares increased 44 cents to $120.78 amid a drop in the broader market.

• ANALYSIS-After tech success, Israel seeks life sciences growth Thursday, 6 Jun 2013 | 6:50 AM ET

  HERZLIYA, Israel, June 6- Inspired by its success in high-tech electronics and software, Israel is hoping to pull off the same trick in life sciences. High-tech has been one of Israel's main growth engines and companies such as Intel Inc, IBM and Google Inc have major R&D centres in the country.

• UPDATE 1-Judge denies FDA bid to stay 'morning-after' pill ruling Friday, 10 May 2013 | 12:19 PM ET

  District Judge Edward Korman in Brooklyn said he would give the FDA until May 13 to ask a federal appeals court in Manhattan to stay the order, which had been scheduled to take effect on Friday.

• Lightning Round: SunTrust, Nokia & More Thursday, 9 May 2013 | 6:42 PM ET

  

  It’s time for the Lightning Round. Cramer makes the call on viewer favorites.

• Lightning Round: Hertz, US Airways & More Wednesday, 8 May 2013 | 6:41 PM ET

  

  It’s time for the Lightning Round. Cramer makes the call on viewer favorites.

• Judge criticizes FDA move on Plan B, agency warns of precedent Tuesday, 7 May 2013 | 4:16 PM ET

  District Judge Edward Korman on April 5 ordered the FDA to lift age restrictions on all levonorgestrel-based emergency contraception- also known as the "morning-after" pill or "Plan B"- to prevent unwanted pregnancies. The FDA has appealed the ruling to the 2nd U.S. Circuit Court of Appeals in Manhattan.

• UPDATE 1-U.S. FDA appeals making 'morning-after' pill available to all ages Wednesday, 1 May 2013 | 8:56 PM ET

  Lawyers with the Justice Department filed the appeal with the 2nd U.S. Circuit Court of Appeals in New York, according to court documents. District Judge Edward Korman's ruling from April 5 that required the FDA to make the emergency contraception available over-the-counter to women of all ages within 30 days.

• FDA files appeal over 'morning-after' pill decision Wednesday, 1 May 2013 | 7:59 PM ET

  Lawyers with the Justice Department filed the appeal with the 2nd U.S. Circuit Court of Appeals in New York, according to court documents. District Judge Edward Korman's ruling from April 5 that required the FDA to make the emergency contraception available over-the-counter to women of all ages within 30 days.

• Drugs from Amgen, others assessed by FDA as radiation treatments Wednesday, 1 May 2013 | 4:16 PM ET

  May 1- Drugs from Amgen Inc, Teva Pharmaceutical Industries and Sanofi that boost white blood cells are being evaluated by U.S. regulators as treatments for radiation exposure caused by a nuclear attack or accident.

• Groups say FDA's Plan B decision falls short of court order Wednesday, 1 May 2013 | 2:45 PM ET

  The FDA said on Tuesday it will allow girls as young as 15 years old to buy without a prescription the Plan B One-Step emergency contraceptive, made by a unit of Teva Pharmaceutical Industries Ltd..

• FDA OKs Morning-After Pill for Girls 15 and Older Wednesday, 1 May 2013 | 11:23 AM ET

  

  The FDA has lowered the age limit for Plan B One-Step emergency contraceptive to 15. The pill will be available without a prescription and stocked on store shelves.

• Fed May Provide a Safety Net for the Market Friday, 26 Apr 2013 | 8:08 PM ET

  

  The Fed is expected to repeat its dovish message in the coming week, which could provide a safety net for the market amid a big wave of earnings and the April jobs report.

• Cramer: Avoid This Drug Stock Thursday, 11 Apr 2013 | 6:57 PM ET

  

  The "Mad Money" host puts this pharmaceutical stock on the "Sell Block."

• TIMELINE-Key dates in legal battle over 'morning-after' pill Friday, 5 Apr 2013 | 12:13 AM ET

  1999: Teva Pharmaceutical Industries Ltd receives FDA approval to market Plan B, the first emergency contraceptive drug for prescription-only use in the United States. 2005: Reproductive-rights groups file lawsuit in Brooklyn federal court seeking to force FDA to respond to their petition.

• UPDATE 2-Obagi Medical gets higher offer from Merz Pharma Tuesday, 2 Apr 2013 | 12:44 AM ET

  April 2- Neurological and dermatology drugs maker Merz Pharma Group offered to buy cosmetic products maker Obagi Medical Products Inc for $383.5 million, topping a bid by Canada's Valeant Pharmaceuticals International Inc. Merz's $22- per-share bid represents a premium of 11 percent to Valeant's offer of $19.75.

• Biogen prices new MS drug at discount to key competitors Friday, 29 Mar 2013 | 1:26 PM ET

  WASHINGTON, March 29- Biogen Idec Inc said on Friday it will charge $54,900 a year for its multiple sclerosis drug, Tecfidera, which received U.S. approval on Wednesday. The company has priced the drug at a discount to key competitors such as Novartis AG's MS pill Gilenya, which costs roughly $60,000 a year, in a bid to maximize its market share.

• UPDATE 2-U.S. FDA approves Biogen's oral MS drug, Tecfidera Wednesday, 27 Mar 2013 | 5:06 PM ET

  *Sales of Tecfidera expected to top $3 billion by 2017. WASHINGTON, March 27- U.S. regulators on Wednesday approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with annual sales topping $3 billion.